Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
CPT Pharmacometrics Syst Pharmacol ; 6(2): 87-109, 2017 02.
Artigo em Inglês | MEDLINE | ID: mdl-27884052

RESUMO

This article represents the first in a series of tutorials on model evaluation in nonlinear mixed effect models (NLMEMs), from the International Society of Pharmacometrics (ISoP) Model Evaluation Group. Numerous tools are available for evaluation of NLMEM, with a particular emphasis on visual assessment. This first basic tutorial focuses on presenting graphical evaluation tools of NLMEM for continuous data. It illustrates graphs for correct or misspecified models, discusses their pros and cons, and recalls the definition of metrics used.


Assuntos
Modelos Biológicos , Farmacocinética , Varfarina/farmacocinética , Feminino , Humanos , Masculino , Dinâmica não Linear , Varfarina/administração & dosagem
2.
Vox Sang ; 108(1): 11-7, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25169580

RESUMO

BACKGROUND AND OBJECTIVES: Donor plasmapheresis involves the removal of a weight-adjusted volume of plasma and the return of cellular components to the donor. Although plasma volume generally returns to normal, some residual effect on vital signs may be possible. This analysis was performed to determine the possible effects of plasmapheresis on blood pressure. MATERIALS AND METHODS: A 16-week study was conducted to evaluate the effects of plasma donations on cholesterol levels in healthy donors. From this study, the vital signs obtained prior to donation were analysed using statistical and dynamic analytical predictive models. RESULTS: Preliminary analyses revealed a change in systolic and diastolic blood pressure from the corresponding baseline values (Pearson Coefficient -0.44 and -0.47, respectively). Statistical models predicted a marked decrease in systolic and diastolic blood pressure following multiple donations in donors with baseline pressure in the Stage 2 hypertension range with less pronounced decreases predicted in Stage 1 donors. Little or no change in blood pressure was predicted in donors with baseline normal blood pressure or prehypertension. Dynamic models including time between donations supported these results and predicted a recovery period of about 14 days without donation in donors with Stage 2 baseline levels. CONCLUSIONS: Results suggest that systolic and diastolic blood pressure may be decreased following plasmapheresis used for plasma donations at intervals of <14 days in donors with high baseline blood pressure levels.


Assuntos
Doadores de Sangue , Pressão Sanguínea , Plasmaferese/efeitos adversos , Adulto , Humanos , Pessoa de Meia-Idade , Modelos Cardiovasculares
3.
Clin Pharmacol Ther ; 86(6): 667-71, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19847163

RESUMO

Teduglutide, a synthetic glucagon-like peptide-2 (GLP-2) analog with activity relating to the regeneration, maintenance, and repair of the intestinal epithelium, is currently being evaluated for the treatment of short-bowel syndrome (SBS), Crohn's disease, and other gastrointestinal disorders. On the basis of promising results from teduglutide studies in adults with SBS and from studies in neonatal and juvenile animal models, a pediatric multiple-dose phase I clinical study was designed to determine the safety, efficacy, and pharmacokinetics of teduglutide in pediatric patients with SBS who have undergone resection for necrotizing enterocolitis, malrotation, or intestinal atresia. This report details the application of clinical trial simulations coupled with a novel approach using generalized additive modeling for location, scale, and shape (GAMLSS) that facilitates the simulation of demographic covariates specific to the targeted patient populations. The goal was to optimize phase I dosing strategies and the likelihood of achieving target exposure and therapeutic effect.


Assuntos
Ensaios Clínicos Fase I como Assunto , Simulação por Computador , Fármacos Gastrointestinais/administração & dosagem , Peptídeo 2 Semelhante ao Glucagon/administração & dosagem , Modelos Biológicos , Peptídeos/administração & dosagem , Síndrome do Intestino Curto/tratamento farmacológico , Adulto , Fatores Etários , Peso Corporal , Cálculos da Dosagem de Medicamento , Fármacos Gastrointestinais/farmacocinética , Peptídeo 2 Semelhante ao Glucagon/farmacocinética , Humanos , Lactente , Recém-Nascido , Peptídeos/farmacocinética , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...